RetinalGenix Technologies and LabCorp Partnership
RetinalGenix Technologies Inc. (OTCQB: RTGN), a leader in ophthalmic research and development, has announced an exciting collaboration with LabCorp, one of the largest laboratory services providers in the country. This partnership focuses on advancing the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, designed for comprehensive genetic and retinal health screening.
Innovative Genetic Testing and Retinal Imaging
This program allows patients to access genetic testing and retinal imaging services at various LabCorp locations. By collecting samples of blood, tears, and saliva, patients can participate in analyses that leverage advanced algorithms created by RetinalGenix. This unique testing capability aims to correlate genetic and retinal biomarkers, establishing a new standard for the early detection of various health conditions.
Patient Empowerment and Confidentiality
One of the standout features of this program is that patients retain complete control over their health records, ensuring anonymity and confidentiality throughout the process. All testing orders and appointments can be managed through the RetinalGenix online platform, delivering results securely once payment is verified at their selected LabCorp center.
Expert Insights from RetinalGenix Leaders
Dr. Larry Perich, a key advisor for the DNA/RNA/GPS initiative, expressed optimism about the collaboration's potential. He remarked that as the database of disease-associated biomarkers grows, so will the diagnostic capabilities of the platform, resulting in improved patient outcomes and access to healthcare.
Dr. Taimour Langaee, PhD, who oversees data processing and genetic association studies, shared his enthusiasm for this initiative. He emphasized the opportunity to broaden understanding of genetics' role in eye diseases and the potential to discover novel genetic variations that could lead to new treatment options.
Enhancing Diagnostic Accuracy
RetinalGenix is also introducing high-resolution retinal imaging as a complementary service in the near future. This enhancement is expected to improve diagnostic accuracy, enabling even general practitioners and eye care clinics to facilitate mass screenings efficiently.
Making Healthcare More Accessible
The innovations spearheaded by RetinalGenix are aimed at making health screening more accessible and affordable. As healthcare costs continue to rise, this methodology seeks to minimize reliance on expensive diagnostic procedures like MRIs and CT scans, thus easing the financial burden on patients and the healthcare system.
According to Jerry Katzman, MD, CEO of RetinalGenix Technologies, establishing CPT codes for their services will help reduce costs and enhance access to necessary evaluations. By streamlining the patient assessment process, this initiative promises to transform the way basic eye care services are delivered, particularly reducing the need for costly specialists.
About RetinalGenix Technologies
As a pioneering company in early disease detection, RetinalGenix integrates advanced genetic screening and imaging techniques to enhance patient care across several diseases. Their innovative high-resolution retinal imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies aim to prevent conditions that could lead to blindness, including various neurodegenerative and cardiovascular disorders.
Furthermore, RetinalGenix is working on therapeutic developments for conditions such as dry age-related macular degeneration (dry AMD) and Alzheimer’s disease, showcasing their commitment to innovative healthcare solutions.
Frequently Asked Questions
What is the focus of the RetinalGenix and LabCorp partnership?
The partnership aims to enhance the DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform for genetic testing and retinal health screening.
How does this program protect patient privacy?
Patients maintain complete control over their health records, ensuring anonymity and confidentiality throughout the testing process.
What types of samples are collected in this testing?
Samples of blood, tears, nasal secretions, and saliva may be collected and analyzed as part of the testing process.
What advancements can patients expect from RetinalGenix?
Patients can look forward to high-resolution retinal imaging services and innovative methodologies that improve diagnostic accuracy and accessibility.
What conditions is RetinalGenix focused on addressing?
The company is focused on early detection and treatment of various ocular and systemic diseases, including diabetes, Alzheimer’s disease, and other eye diseases.
